Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome (NCT03708900)
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome
🩺 Plain-English Summary (8th-Grade Level)
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
Who can join: Review the eligibility criteria below.
Location: University of California San Francisco UCSF — San Francisco, California
Age range: 2 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- University of California San Francisco UCSF — San Francisco, California
- ABMED Clinical Research Corp — Cape Coral, Florida
- Ann & Robert H. Lurie Children's Hospital — Chicago, Illinois
- National Institute of Child Health and Human Development — Bethesda, Maryland
- Texas Valley Clinical Research — Weslaco, Texas
- UZ Brussel — Jette, Brussels Capital
- Multiprofile Hospital for Active Treatment Sveta Marina EAD — Varna,
- Hospital Necker Enfants Malades — Paris,
- Robert Debre Hospital — Paris,
- CHU Bicetre APHP Paris Saclay — Paris,
- Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello — Pisa, PI
- Ospedale Bambino Gesu — Roma,
- University Clinical Center Ljubljana — Ljubljana,
- Alder Hey Childrens NHS Foundation Trust — Liverpool,
- The Royal London Childrens Hospital — London,
📞 Contact the Study Coordinator
Phone: +39 0248787456
Email: casi.m@recordati.it
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cushing Syndrome
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome — Phoenix, Arizona
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome — Bethesda, Maryland
- Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS) — Rochester, Minnesota
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome — Bethesda, Maryland
Explore by condition: All Cushing Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.